JP2024509981A5 - - Google Patents
Info
- Publication number
- JP2024509981A5 JP2024509981A5 JP2023556474A JP2023556474A JP2024509981A5 JP 2024509981 A5 JP2024509981 A5 JP 2024509981A5 JP 2023556474 A JP2023556474 A JP 2023556474A JP 2023556474 A JP2023556474 A JP 2023556474A JP 2024509981 A5 JP2024509981 A5 JP 2024509981A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- membered
- pharmaceutically acceptable
- hydrogen
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025056015A JP2025106341A (ja) | 2021-03-15 | 2025-03-28 | ピラゾロピリジン誘導体及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163161139P | 2021-03-15 | 2021-03-15 | |
| US63/161,139 | 2021-03-15 | ||
| US202163164130P | 2021-03-22 | 2021-03-22 | |
| US63/164,130 | 2021-03-22 | ||
| PCT/IB2022/052281 WO2022195454A1 (en) | 2021-03-15 | 2022-03-14 | Pyrazolopyridine derivatives and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025056015A Division JP2025106341A (ja) | 2021-03-15 | 2025-03-28 | ピラゾロピリジン誘導体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024509981A JP2024509981A (ja) | 2024-03-05 |
| JP2024509981A5 true JP2024509981A5 (cg-RX-API-DMAC7.html) | 2024-03-28 |
| JP7659648B2 JP7659648B2 (ja) | 2025-04-09 |
Family
ID=80819999
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023556474A Active JP7659648B2 (ja) | 2021-03-15 | 2022-03-14 | ピラゾロピリジン誘導体及びその使用 |
| JP2025056015A Pending JP2025106341A (ja) | 2021-03-15 | 2025-03-28 | ピラゾロピリジン誘導体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025056015A Pending JP2025106341A (ja) | 2021-03-15 | 2025-03-28 | ピラゾロピリジン誘導体及びその使用 |
Country Status (20)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021255160B2 (en) | 2020-04-13 | 2024-02-01 | Aptabio Therapeutics Inc. | Pulmonary fibrosis medicine containing pyrazole derivative |
| EP4308559A1 (en) * | 2021-03-15 | 2024-01-24 | Novartis AG | Benzisoxazole derivatives and uses thereof |
| UY39671A (es) | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
| PE20240822A1 (es) | 2021-03-22 | 2024-04-18 | Neurocrine Biosciences Inc | Inhibidores de vmat2 y metodos de uso |
| CN120129677A (zh) | 2022-11-04 | 2025-06-10 | 百时美施贵宝公司 | 化合物及其用于治疗血红素病变的用途 |
| WO2024255810A1 (en) * | 2023-06-15 | 2024-12-19 | Hangzhou Glubio Pharmaceutical Co., Ltd | Dihydropyrimidine-2, 4 (1h, 3h) -dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof |
| WO2026136866A1 (en) | 2024-12-20 | 2026-06-25 | Prelude Therapeutics Incorporated | Kat6 targeting compounds |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| BRPI0417186A (pt) | 2003-12-02 | 2007-03-06 | Celgene Corp | método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica |
| EP1604988A1 (en) | 2004-05-18 | 2005-12-14 | Sanofi-Aventis Deutschland GmbH | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
| CN102089291B (zh) | 2008-04-28 | 2016-08-17 | 杏林制药株式会社 | 环戊基丙烯酰胺衍生物 |
| EP2165707A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| SG183257A1 (en) | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| ES2689429T3 (es) | 2012-07-13 | 2018-11-14 | Ucb Biopharma Sprl | Derivados de imidazopiridina como moduladores de actividad de TNF |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| TWI793151B (zh) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| JP2020009513A (ja) * | 2018-07-10 | 2020-01-16 | キオクシア株式会社 | メモリシステム |
| AR116109A1 (es) * | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| KR102980990B1 (ko) | 2019-04-05 | 2026-06-25 | 카이메라 쎄라퓨틱스 인코포레이티드 | Stat 분해제 및 이의 용도 |
| EP3969458A4 (en) | 2019-05-13 | 2023-05-17 | Borah, Inc. | CHEMICAL COMPOUNDS |
| PH12022551482A1 (en) | 2019-12-18 | 2023-11-29 | Novartis Ag | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP4100394B1 (en) | 2020-02-04 | 2026-04-08 | Stingray Therapeutics, Inc. | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of use thereof |
| US20230089530A1 (en) | 2020-02-09 | 2023-03-23 | Newave Pharmaceutical Inc. | Quinuclidinone analogues as anticancer agents |
| UY39671A (es) | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
-
2022
- 2022-03-11 UY UY0001039671A patent/UY39671A/es unknown
- 2022-03-11 PY PY202202217419A patent/PY2217419A/es unknown
- 2022-03-14 TW TW111109165A patent/TWI923713B/zh active
- 2022-03-14 AU AU2022239950A patent/AU2022239950B2/en active Active
- 2022-03-14 JP JP2023556474A patent/JP7659648B2/ja active Active
- 2022-03-14 CA CA3208951A patent/CA3208951A1/en active Pending
- 2022-03-14 US US17/693,759 patent/US11787785B2/en active Active
- 2022-03-14 IL IL305931A patent/IL305931A/en unknown
- 2022-03-14 KR KR1020237034868A patent/KR102902295B1/ko active Active
- 2022-03-14 MX MX2023010827A patent/MX2023010827A/es unknown
- 2022-03-14 EP EP22711643.1A patent/EP4308562A1/en active Pending
- 2022-03-14 CR CR20230486A patent/CR20230486A/es unknown
- 2022-03-14 WO PCT/IB2022/052281 patent/WO2022195454A1/en not_active Ceased
- 2022-03-14 PE PE2023002595A patent/PE20242203A1/es unknown
-
2023
- 2023-07-21 ZA ZA2023/07290A patent/ZA202307290B/en unknown
- 2023-09-01 US US18/460,428 patent/US12172984B2/en active Active
- 2023-09-13 DO DO2023000188A patent/DOP2023000188A/es unknown
- 2023-09-13 CL CL2023002726A patent/CL2023002726A1/es unknown
- 2023-09-14 JO JOJO/P/2023/0218A patent/JOP20230218A1/ar unknown
- 2023-10-12 CO CONC2023/0013486A patent/CO2023013486A2/es unknown
- 2023-10-12 EC ECSENADI202376800A patent/ECSP23076800A/es unknown
-
2024
- 2024-09-06 US US18/826,887 patent/US12252482B2/en active Active
- 2024-11-06 US US18/939,314 patent/US20250282762A1/en active Pending
- 2024-12-09 AU AU2024278210A patent/AU2024278210B2/en active Active
-
2025
- 2025-03-28 JP JP2025056015A patent/JP2025106341A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024520654A5 (cg-RX-API-DMAC7.html) | ||
| US11299480B2 (en) | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | |
| EP3630101B1 (en) | Tegavivint for use in the treatment of pulmonary fibrosis | |
| TW200934782A (en) | 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use | |
| RU2010126063A (ru) | Производные 4-(2-амино-1-гидроксиэтил)фенола как агонисты в2 адренергического рецептора | |
| US11434205B2 (en) | Substituted imidazole carboxylate derivatives and the use thereof | |
| RU2006128426A (ru) | Производные тиофенав в качестве ингибиторов снк 1 | |
| JP2018109017A5 (cg-RX-API-DMAC7.html) | ||
| RU2006113700A (ru) | Аминозамещенный этиламито-агонисты бэта2-адренергических рецепторов | |
| JP7080346B2 (ja) | 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Bclファミリーアンタゴニストであるホスホノアミダート | |
| JP2009526831A5 (cg-RX-API-DMAC7.html) | ||
| JP2016128481A (ja) | 肺高血圧症の処置のためのニトロキシル供与体 | |
| EP4201941B1 (en) | Pyrazole boronic acid compound, pharmaceutical composition containing same, and uses thereof | |
| RU2004104329A (ru) | Ацилсемикарбазиды как ингибиторы циклинзависимой киназы, полезные в качестве противораковых и противопролиферативных агентов | |
| CN115605210A (zh) | 用于治疗心律失常的烟酰胺单核苷酸和双烟酰胺二核苷酸衍生物 | |
| JP2004524345A5 (cg-RX-API-DMAC7.html) | ||
| JP2024509625A5 (cg-RX-API-DMAC7.html) | ||
| JP2017137323A (ja) | 新規抗がん剤 | |
| JP2022541311A5 (cg-RX-API-DMAC7.html) | ||
| JP2026510456A (ja) | Ampk活性化および/またはchop阻害により処置できる疾患および障害の処置のためのセフィン1および関連化合物 | |
| RU2732417C1 (ru) | Производные фенотиазина и способы их применения | |
| WO2022109311A1 (en) | Methods and materials for increasing nicotinamide phosphoribosyltransferase activity | |
| JP2008538099A5 (cg-RX-API-DMAC7.html) | ||
| US20250002512A1 (en) | Novel anti-depressant and neuroplastic agents and therapeutic uses thereof | |
| JP5198852B2 (ja) | 脳梗塞に関連する脳血管障害の治療に有用なピラゾロン化合物 |